Switch theme
Sign up to access all valuation multiples
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in two segments: proton therapy and other accelerators and dosimetry. Proton therapy and other accelerators business contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, and the Rest of the World.
1986
2.1K+
LTM Revenue $595M
LTM EBITDA $40.5M
$366M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
IBA Group has a last 12-month revenue (LTM) of $595M and a last 12-month EBITDA of $40.5M.
In the most recent fiscal year, IBA Group achieved revenue of $560M and an EBITDA of $32.3M.
IBA Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IBA Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $595M | XXX | $560M | XXX | XXX | XXX |
| Gross Profit | $197M | XXX | $186M | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $40.5M | XXX | $32.3M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBIT | $26.4M | XXX | $11.1M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $14.8M | XXX | $10.4M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, IBA Group's stock price is EUR 12 (or $14).
IBA Group has current market cap of EUR 354M (or $398M), and EV of EUR 325M (or $366M).
See IBA Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $366M | $398M | XXX | XXX | XXX | XXX | $0.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, IBA Group has market cap of $398M and EV of $366M.
IBA Group's trades at 0.7x EV/Revenue multiple, and 11.3x EV/EBITDA.
Equity research analysts estimate IBA Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IBA Group has a P/E ratio of 26.8x.
See valuation multiples for IBA Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $398M | XXX | $398M | XXX | XXX | XXX |
| EV (current) | $366M | XXX | $366M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | 11.3x | XXX | XXX | XXX |
| EV/EBIT | 13.9x | XXX | 32.9x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 26.8x | XXX | 38.3x | XXX | XXX | XXX |
| EV/FCF | -30.6x | XXX | -18.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIBA Group's last 12 month revenue growth is 11%
IBA Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
IBA Group's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IBA Group's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for IBA Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 30% | XXX | 84% | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IBA Group acquired XXX companies to date.
Last acquisition by IBA Group was XXXXXXXX, XXXXX XXXXX XXXXXX . IBA Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was IBA Group founded? | IBA Group was founded in 1986. |
| Where is IBA Group headquartered? | IBA Group is headquartered in Belgium. |
| How many employees does IBA Group have? | As of today, IBA Group has 2.1K+ employees. |
| Who is the CEO of IBA Group? | IBA Group's CEO is Mr. Olivier Legrain. |
| Is IBA Group publicy listed? | Yes, IBA Group is a public company listed on BRU. |
| What is the stock symbol of IBA Group? | IBA Group trades under IBAB ticker. |
| When did IBA Group go public? | IBA Group went public in 1998. |
| Who are competitors of IBA Group? | Similar companies to IBA Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of IBA Group? | IBA Group's current market cap is $398M |
| What is the current revenue of IBA Group? | IBA Group's last 12 months revenue is $595M. |
| What is the current revenue growth of IBA Group? | IBA Group revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of IBA Group? | Current revenue multiple of IBA Group is 0.6x. |
| Is IBA Group profitable? | Yes, IBA Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of IBA Group? | IBA Group's last 12 months EBITDA is $40.5M. |
| What is IBA Group's EBITDA margin? | IBA Group's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of IBA Group? | Current EBITDA multiple of IBA Group is 9.0x. |
| What is the current FCF of IBA Group? | IBA Group's last 12 months FCF is -$11.9M. |
| What is IBA Group's FCF margin? | IBA Group's last 12 months FCF margin is -2%. |
| What is the current EV/FCF multiple of IBA Group? | Current FCF multiple of IBA Group is -30.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
